Pacira BioSciences - PCRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.40
  • Forecasted Upside: 58.32%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$29.94
▼ -0.38 (-1.25%)

This chart shows the closing price for PCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

Analyst Price Target is $47.40
▲ +58.32% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $47.40, with a high forecast of $57.00 and a low forecast of $38.00. The average price target represents a 58.32% upside from the last price of $29.94.

This chart shows the closing price for PCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Pacira BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$57.00Low
5/8/2024BarclaysLower TargetOverweight ➝ Overweight$40.00 ➝ $38.00Low
5/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$45.00 ➝ $43.00Low
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00Low
3/7/2024JPMorgan Chase & Co.Initiated CoverageOverweight$80.00 ➝ $45.00Low
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$57.00Low
3/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$53.00 ➝ $45.00Low
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00Low
2/8/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00Low
1/5/2024WedbushReiterated RatingOutperform$57.00Low
12/20/2023Raymond JamesInitiated CoverageOutperform$42.00Low
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $57.00Low
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$50.00 ➝ $42.00Low
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$67.00 ➝ $58.00Low
11/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$52.00 ➝ $45.00N/A
10/23/2023BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $57.00Low
10/3/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$68.00Low
8/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$60.00 ➝ $50.00Low
8/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$70.00 ➝ $68.00Low
8/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$60.00 ➝ $52.00Low
8/3/2023Truist FinancialLower TargetBuy ➝ Buy$60.00 ➝ $55.00N/A
8/3/2023TD CowenUpgradeMarket Perform ➝ Outperform$50.00Low
8/3/2023HC WainwrightLower TargetBuy ➝ Buy$68.00 ➝ $63.00Low
7/13/2023HC WainwrightLower Target$71.00 ➝ $68.00Low
4/25/2023Piper SandlerLower Target$63.00 ➝ $62.00Low
4/20/2023Needham & Company LLCReiterated RatingBuy$60.00Low
3/3/2023BarclaysLower Target$90.00 ➝ $80.00Low
3/1/2023Royal Bank of CanadaLower TargetOutperform$80.00 ➝ $76.00Low
3/1/2023HC WainwrightBoost TargetBuy$69.00 ➝ $71.00Low
2/28/2023Needham & Company LLCLower TargetBuy$63.00 ➝ $60.00Low
2/10/2023HC WainwrightLower TargetBuy$76.00 ➝ $69.00Low
1/31/2023WedbushReiterated RatingOutperform$60.00Low
1/18/2023Truist FinancialLower Target$68.00 ➝ $63.00Low
1/6/2023BMO Capital MarketsLower TargetMarket Perform$60.00 ➝ $52.00Low
1/6/2023Needham & Company LLCLower TargetBuy$66.00 ➝ $63.00Low
12/21/2022WedbushReiterated RatingBuy$88.00Low
12/14/2022CowenLower Target$54.00 ➝ $50.00Low
12/14/2022CowenLower Target$54.00 ➝ $50.00Low
11/7/2022BMO Capital MarketsLower TargetMarket Perform$66.00 ➝ $60.00Low
11/4/2022HC WainwrightLower TargetBuy$83.00 ➝ $76.00N/A
11/3/2022Needham & Company LLCLower TargetBuy$76.00 ➝ $74.00Low
10/21/2022Jefferies Financial GroupInitiated CoverageBuy$66.00Low
9/21/2022WedbushReiterated RatingOutperform$94.00Low
7/21/2022Piper SandlerLower TargetOverweight$84.00 ➝ $80.00Low
6/15/2022Needham & Company LLCLower TargetBuy$84.00 ➝ $76.00High
3/1/2022Northland SecuritiesBoost Target$61.00 ➝ $67.00High
2/26/2022WedbushReiterated RatingBuy$97.00 ➝ $94.00Medium
2/25/2022HC WainwrightBoost TargetBuy$86.00 ➝ $90.00High
2/16/2022WedbushReiterated RatingBuy$97.00Low
1/19/2022BarclaysBoost TargetOverweight$92.00 ➝ $96.00Low
1/7/2022WedbushReiterated RatingBuy$97.00High
1/4/2022Northland SecuritiesBoost Target$57.00 ➝ $61.00Medium
1/3/2022JPMorgan Chase & Co.Initiated CoverageOverweight$83.00Medium
11/5/2021BarclaysBoost TargetOverweight$91.00 ➝ $92.00High
11/4/2021HC WainwrightBoost TargetBuy$80.00 ➝ $86.00Low
10/18/2021Needham & Company LLCBoost TargetBuy$80.00 ➝ $84.00Low
10/12/2021HC WainwrightLower TargetBuy$84.00 ➝ $80.00Medium
10/12/2021BMO Capital MarketsLower TargetMarket Perform$66.00 ➝ $60.00Medium
10/5/2021Northland SecuritiesLower TargetMarket Perform$66.00 ➝ $57.00High
10/1/2021BarclaysLower TargetOverweight$95.00 ➝ $91.00High
9/22/2021WedbushReiterated RatingBuy$93.00Low
8/4/2021HC WainwrightLower TargetBuy$86.00 ➝ $84.00Medium
7/26/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$70.00 ➝ $75.00Low
7/14/2021HC WainwrightReiterated RatingBuy$86.00Low
5/10/2021BMO Capital MarketsLower TargetMarket Perform$72.00 ➝ $70.00Medium
5/5/2021Northland SecuritiesLower TargetMarket Perform$75.00 ➝ $66.00Low
4/9/2021Berenberg BankInitiated CoverageBuy$93.00Low
3/1/2021HC WainwrightBoost TargetBuy$70.00 ➝ $86.00Low
2/26/2021BarclaysBoost TargetOverweight$79.00 ➝ $94.00Medium
2/11/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$72.00 ➝ $75.00Low
1/25/2021Northland SecuritiesBoost TargetOutperform$67.00 ➝ $72.00Medium
1/21/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$63.00 ➝ $75.00High
1/20/2021Piper SandlerBoost TargetOverweight$65.00 ➝ $90.00Low
1/8/2021Needham & Company LLCBoost TargetBuy$67.00 ➝ $76.00High
1/6/2021Royal Bank of CanadaBoost TargetOutperform$65.00 ➝ $70.00N/A
12/14/2020BarclaysBoost TargetOverweight$73.00 ➝ $79.00Low
12/9/2020Needham & Company LLCLower TargetBuy$68.00 ➝ $67.00High
11/2/2020WedbushLower TargetOutperform$85.00 ➝ $83.00Low
10/7/2020WedbushReiterated RatingBuy$85.00Medium
9/30/2020Jefferies Financial GroupBoost Target$69.00 ➝ $75.00Low
9/21/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$58.00 ➝ $67.00Medium
9/9/2020Needham & Company LLCBoost TargetBuy$64.00 ➝ $68.00High
8/17/2020WedbushReiterated RatingBuy$85.00Medium
8/14/2020Truist FinancialBoost Target$54.00 ➝ $65.00Low
8/10/2020HC WainwrightBoost TargetBuy$68.00 ➝ $70.00High
7/20/2020WedbushReiterated RatingBuy$85.00Low
7/13/2020HC WainwrightReiterated RatingBuy$63.00 ➝ $68.00High
7/10/2020Jefferies Financial GroupBoost TargetBuy$53.00 ➝ $69.00Low
7/6/2020Needham & Company LLCBoost TargetBuy$52.00 ➝ $64.00Medium
7/6/2020Piper SandlerBoost TargetPositive ➝ Overweight$49.00 ➝ $65.00Medium
7/2/2020WedbushReiterated RatingBuy$85.00N/A
7/1/2020Royal Bank of CanadaBoost TargetOutperform$56.00 ➝ $62.00High
6/30/2020SVB LeerinkBoost TargetOutperform$45.00 ➝ $58.00Medium
6/30/2020Northland SecuritiesBoost TargetMarket Perform$50.00 ➝ $54.00Low
5/27/2020Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
5/26/2020GuggenheimInitiated CoverageNeutralLow
5/13/2020Royal Bank of CanadaReiterated RatingBuy$56.00High
5/12/2020WedbushReiterated RatingBuy$85.00High
5/8/2020SVB LeerinkBoost TargetBuy$44.00 ➝ $45.00Medium
5/7/2020Stifel NicolausLower TargetHold$49.00 ➝ $48.00Low
4/30/2020Needham & Company LLCLower TargetBuy$56.00 ➝ $52.00High
4/27/2020WedbushReiterated RatingBuy$85.00Medium
4/17/2020Northland SecuritiesReiterated RatingBuy$50.00High
4/7/2020Northland SecuritiesInitiated CoverageOutperform$50.00High
3/23/2020Piper SandlerLower Target$60.00 ➝ $49.00High
3/23/2020Royal Bank of CanadaLower TargetOutperform$65.00 ➝ $56.00High
3/20/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$46.00 ➝ $44.00High
2/24/2020HC WainwrightBoost TargetBuy$60.00 ➝ $63.00Medium
2/20/2020WedbushReiterated RatingBuy$85.00N/A
2/20/2020Stifel NicolausReiterated RatingHold$49.00High
2/20/2020Piper SandlerBoost TargetBuy$54.00 ➝ $60.00Low
1/23/2020SunTrust BanksInitiated CoverageBuy$60.00Low
1/7/2020WedbushReiterated RatingBuy$85.00Low
12/18/2019Royal Bank of CanadaReiterated RatingBuyLow
12/17/2019WedbushReiterated RatingBuy$85.00Medium
11/8/2019BarclaysBoost TargetOverweight$52.00 ➝ $55.00Medium
11/7/2019Needham & Company LLCReiterated RatingBuy$56.00High
11/7/2019CowenReiterated RatingHold$41.00High
11/6/2019BTIG ResearchInitiated CoverageBuy$56.00 ➝ $56.00Medium
10/8/2019Jefferies Financial GroupSet TargetBuy$60.00Low
8/9/2019Stifel NicolausSet TargetHold$42.00Low
8/9/2019BMO Capital MarketsLower TargetMarket Perform$46.00 ➝ $43.00Low
6/28/2019WedbushSet TargetBuy$85.00Medium
6/12/2019WedbushReiterated RatingOutperform$85.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$52.00Low
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/27/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/26/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 20 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 13 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/25/2024
  • 6 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/24/2024
  • 12 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024

Current Sentiment

  • 12 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Pacira BioSciences logo
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $29.94
Low: $29.83
High: $30.50

50 Day Range

MA: $28.37
Low: $25.50
High: $31.51

52 Week Range

Now: $29.94
Low: $25.33
High: $41.65

Volume

47,509 shs

Average Volume

594,237 shs

Market Capitalization

$1.39 billion

P/E Ratio

20.94

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, TD Cowen, TheStreet, Truist Financial Co., and Wedbush.
View the latest analyst ratings for PCRX.

What is the current price target for Pacira BioSciences?

10 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $47.40, suggesting a possible upside of 58.3%. Wedbush has the highest price target set, predicting PCRX will reach $57.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $38.00 for Pacira BioSciences in the next year.
View the latest price targets for PCRX.

What is the current consensus analyst rating for Pacira BioSciences?

Pacira BioSciences currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.

What other companies compete with Pacira BioSciences?

How do I contact Pacira BioSciences' investor relations team?

Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is (813) 553-6680 and its investor relations email address is [email protected]. The official website for Pacira BioSciences is www.pacira.com. Learn More about contacing Pacira BioSciences investor relations.